

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041305 A1

(51) International Patent Classification⁷: **A61K 39/05**,
39/07, 35/74, A01N 63/00, A23L 1/03, C12N 1/20

(21) International Application Number:
PCT/FI2003/000813

(22) International Filing Date:
3 November 2003 (03.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20021968 4 November 2002 (04.11.2002) FI

(71) Applicant (for all designated States except US): **VALIO LTD** [FI/FI]; Meijeritie 6, FIN-00370 Helsinki (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SUOMALAINEN, Tarja** [FI/FI]; Lallukantie 1 C, FIN-00740 Helsinki (FI). **MÄYRÄ-MÄKINEN, Annika** [FI/FI]; Maurinkatu 4 B 19, FIN-00170 Helsinki (FI).

(74) Agent: **KOLSTER OY AB**; Iso Roobertinkatu 23, P.O. Box 148, FIN-00121 Helsinki (FI).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT (utility model), PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO utility model (BW), ARIPO patent (BW), ARIPO utility model (GH), ARIPO

patent (GH), ARIPO utility model (GM), ARIPO patent (GM), ARIPO utility model (KE), ARIPO patent (KE), ARIPO utility model (LS), ARIPO patent (LS), ARIPO utility model (MW), ARIPO patent (MW), ARIPO utility model (MZ), ARIPO patent (MZ), ARIPO utility model (SD), ARIPO patent (SD), ARIPO utility model (SL), ARIPO patent (SL), ARIPO utility model (SZ), ARIPO patent (SZ), ARIPO utility model (TZ), ARIPO patent (TZ), ARIPO utility model (UG), ARIPO patent (UG), ARIPO utility model (ZM), ARIPO patent (ZM), ARIPO utility model (ZW), ARIPO patent (ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR INHIBITING YEAST GROWTH

(57) Abstract: The invention relates to the use of microbes *Lactobacillus rhamnosus* LGG, ATCC 53103, *Lactobacillus rhamnosus* LC705, DSM 7061, and *Propionibacterium freudenreichii* ssp. *shermanii* PJS, DSM 7067 for inhibiting yeast growth, for preventing and treating diseases caused by yeast and for relieving yeast-related symptoms in animals or humans.

WO 2004/041305 A1

METHOD FOR INHIBITING YEAST GROWTH

FIELD OF THE INVENTION

[0001] The invention relates to inhibiting the growth of yeasts. In particular, products and methods for inhibiting the growth of yeasts and for preventing and treating diseases caused by yeasts are disclosed.

BACKGROUND OF THE INVENTION

[0002] Yeasts are constantly present in the living environment and the organ system of humans. Even a healthy individual has *Candida albicans* yeast growing on the mucosal membrane and in the entire area of the gastrointestinal tract (Shay K, Truhlar MR, Renner RP. Oropharyngeal candidosis in the older people. *J Am Geriatr Soc* 1997;45:863-870). The oral cavity and the tissue between teeth also provide an excellent growth medium for a number of species of microbes, among which can be found for example the *Candida albicans* species and, to a lesser amount, *C. glabrata* and *C. tropicalis* yeasts. Normally yeast cells are in a passive state and their growth does not harm healthy individuals. In unfavourable conditions yeasts, such as *C. albicans*, begin to form hyphae and thereby penetrate deeper into the mucosal membranes. This results in a local yeast infection, which in the mouth appears for example as oral candidiasis, stomatitis, or glossitis.

[0003] Yeast infections are usually preceded by reduced resistance, which may be caused by certain medication, for example use of broad-spectrum antibiotics, corticosteroids or cytostatics, by diabetes, malign tumors, or immunodeficiency. Micro-organisms of the mouth spread easily, carried by blood circulation, to other parts of the organ system, which may have severe consequences, such as septicemia, endocarditis and meningitis, particularly in persons whose general state of health has deteriorated (Shay et al. 1997).

[0004] The most common and most important cause of yeast infections in humans is *Candida albicans* (Mäkelä et al. 1988. Lääketieteellinen mikrobiologia (Medical microbiology), 5th revised edition, pp. 270-271. Published by Kustannus Oy Duodecim 1988). *C. albicans* can be found relatively often in the gastrointestinal tract of healthy humans: 30 to 50% carry it in the mouth and about 1% on healthy skin and in the urinary tract. Also other species of the *Candida* genus can be found occasionally, the most important ones being: *C. tropicalis*, *C. pseudotropicalis*, *C. parapsilosis*, *C. krusei*, and *C.*

guilliermondi, which act as opportunistic pathogens in humans, similarly as *C. albicans* (Mäkelä et al. 1988).

[0005] Elderly people typically suffer from a number of diseases, which, together with the medication used for treating them, may weaken their immunity and, at the same time, their dental health (Pajukoski H, Meurman JH, Snellman-Gröhn S, Sulkava R. Oral health in hospitalized and nonhospitalized community-dwelling elderly patients. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999;88:437-443). In addition, poor dental hygiene submits elderly people to yeast infections (Budtz-Jorgensen E, Mojon P, Banon-Clement JM, Baehni P. Oral candidosis in long-term hospital care: comparison of edentulous and dentate subjects. *Oral Dis* 1996;2:285-290). Ageing as such increases the appearance of yeast and the amount of it, which implies that the ability of the organ system to inhibit yeast growth reduces with age (Lockhart SR, Joly S, Vargas K, Swails-Wenger J, Enger L, Soil DR. Natural defenses against *Candida* colonization breakdown in the oral cavities of the elderly. *J Dent Res* 1999;78:857-868).

[0006] In elderly people living in Helsinki, Finland, yeast growth was found in 75%, high contents being found in 33% (Närhi TO, Ainamo A, Meurman JH. Salivary yeasts, saliva, and oral mucosa in the elderly. *J Dent Res* 1993;72:1009-1014). *Candida* yeast infection, in turn, has been found in 60% of those who carry yeast (Wilkieson C, Samaranayake LP, MacFarlane TW, Larney PJ, etc. Oral candidosis in the elderly in long term hospital care. *J Oral Pathol Med* 1991;20:13-16). The most common yeasts after *Candida albicans* are *C. glabrata* (29%), *C. tropicalis* (13%), *Saccharomyces cerevisiae* (11%), and *C. parapsilosis* 89%) (Lockhart et al. 1999).

[0007] One important factor increasing oral yeast growth is reduced salivation (Närhi et al. 1993). A five-year follow-up study of the effects of ageing showed that stimulated secretion of total saliva reduces with ageing, whereas buffer capacity increases (Närhi TO, Kurki N, Ainamo A. Saliva, salivary micro-organisms, and oral health in the home-dwelling old elderly - a five-year longitudinal study. *J Dent Res* 1999;78:1640-1646). Endocrinological diseases and abundant use of medication in particular reduce salivation (Pajukoski H, Meurman JH, Snellman-Gröhn S, Keinänen S, Sulkava R. Salivary flow and composition in elderly patients referred to an acute care geriatric ward. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1997; 84: 265-71). Yeast contents are clearly higher for those whose rate of salivation and buffer

capacity has reduced (Närhi et al. 1993). The rate of salivation of elderly Finns varies between 0.6 and 1.0 ml/mm (Pajukoski et al. 1997); reduced secretion (< 0.7 ml/mm) is found with as much as 55% and low buffer capacity with 34% of the elderly (Pajukoski et al. 1997).

5 **[0008]** Candidosis has conventionally been treated with antifungal agents, such as nystatin, and more severe cases with fluconazole or itraconazole (Shay et al. 1997). Also more efficient oral hygiene has enabled to reduce
10 *Candida* colonization in the oral mucosal membranes of elderly confined in long-term care (Budtz-Jorgensen E, Mojon P, Rentsch A, Deslauriers N. Effects of an oral health program on the occurrence of oral candidosis on a long-term care facility. *Community Dent Oral Epidemiol* 2000;28:141-149). The use of chlorhexidine/xylitol chewing-gum also enabled the amount of yeast to be reduced by 22% (Simons D, Kidd EAM, Beighton D, Jones B. The effect of chlorhexidine/xylitol chewing-gum on cariogenic salivary microflora: A clinical
15 trial in elderly patients. *Caries Res* 1997;31:91-96).

[0009] Certain groups, such as patients in long-term care and elderly people, are also prone to general infections due to reduced immunity, malnutrition and chronic diseases. In addition, in elderly people oral hygiene and oral microbial flora have been found to be associated with infections of the
20 lower respiratory ducts, such as pneumonia and bronchitis (see Scannapieco FA. Role of oral bacteria in respiratory infection. *J Periodontol* 1999;70:793-802). An infection is presumably caused when pathogenic microbes are transferred through aspiration from the mouth to the respiratory ducts. The most common infections affecting patients in long-term care are: infections of the
25 upper and lower respiratory ducts (70%), infections of the urinary tract (12%), gastroenteritis and diarrhea (12%) as well as dermatitis and infections of the soft tissue (6%) (Orr PH, Nicolle LE, Duckworth H, Brunka J, Kennedy J, Murray D et al. Febrile urinary infection in the institutionalized elderly. *Am J Med* 1996;100:71-77). Hygiene intervention has enabled to reduce infections
30 of the upper respiratory ducts of elderly people in long-term hospital care by 16% (Makris AT, Morgan L, Gaber DJ, Richter A, Rubino JR, Effect of comprehensive infection control program on the incidence of infections in long-term care facilities. *Am J Infect Control* 2000;28:3-7).

[0010] Another main area where yeast appears is the genital area;
35 in women in particular yeast infections are common. The most common gynecological symptom is vaginitis; it is also one of the main symptoms of patients

who seek medical consultation (Mäkelä et al. 1988). Vaginitis is most commonly caused by a bacterium, the second most common cause being a yeast fungus, *C. albicans* and *C. glabrata* being the species that appear most often. *Candida albicans* is a yeast that belongs to the normal microflora of the vagina, and normally it does not cause infections. Usually the bacterial flora of the vagina restricts yeast growth, but in certain conditions yeast growth becomes excessive. Risk factors for a yeast infection include use of antibiotics (particularly broad-spectrum antibiotics), pregnancy, diabetes, diseases that cause immune deficiency, and use of corticosteroids. Yeast fungus can be found in 10 to 20% of patients at gynaecological outpatient departments, but only some of them become affected by a clinical vulvovaginitis caused by yeast. A basic pH favours yeast growth. The virulence of yeast depends on the yeast content, the invasiveness of its mycelium, its steroid receptors, and on the ability of yeast to form proteases, for example. Research has shown that fungal hyphae are capable of penetrating the vaginal epithelium (Mäkelä et al. 1988).

[0011] Lactic acid bacteria have been used with varying results for preventing vaginitis. Yoghurt intake for 6 months reduced *Candida* colonization and the occurrences of vaginitis (Hilton et al. 1992. Ingestion of yoghurt containing *Lactobacillus acidophilus* as prophylaxis for Candidal vaginitis. *Ann Intern Med* 1992;116:353-357). On the other hand, according to the research carried out by the Shalev group (1996) *Lactobacillus acidophilus* yoghurt, in comparison with pasteurized yoghurt, reduced vaginitis caused by bacteria, but not that caused by *Candida* yeast (Shalev et al. 1996. Ingestion of yoghurt containing *Lactobacillus acidophilus* compared with pasteurized yoghurt as prophylaxis for recurrent Candidal vaginitis and bacterial vaginosis. *Arch Fam Med* 1996;5:593-596; Sieber R, Dietz U-T. *Lactobacillus acidophilus* and yogurt in the prevention and therapy of bacterial vaginosis. *Int Dairy J* 1998; 8:599-607; see also Redondo-Lopez et al. 1990. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. *Rev Infect Dis* 1990;12:856-872).

[0012] Yeast fungus also causes urethritis.

[0013] Several studies have shown that 20 - 40% of people carry *C. albicans* in the gastrointestinal tract (Lennette et al. 1985. Manual of clinical microbiology, 4th edition. American Society for Microbiology, Washington D.C., 1985). Overgrowth of yeast in the gastrointestinal tract manifests itself usually as diarrhea.

[0014] The term 'yeast syndrome' is usually used to refer to increased growth of *Candida albicans* yeast in the gastrointestinal tract, which is considered to inhibit the immune system and to cause different syndromes. Yeast overgrowth has been associated with a number of systemic symptoms, such as symptoms of the central nervous system, different aches, fatigue and symptoms of the intestines. It is assumed that the symptoms are due to toxins released by yeasts. However, there is no scientific evidence of a connection between such symptoms and yeast. Yeast syndrome is treated with a low-carbohydrate, yeast-free diet, possibly favouring soured and/or fibre-rich nutrients. Soured foods and soured dairy products in particular form an important element of the diet treatment. Consequently, lactic acid bacteria are often used to balance a disturbed intestinal flora.

[0015] Yeast thus causes many kinds of diseases, both indirectly and directly. There is therefore a constant need to find new means for inhibiting yeast growth and activity, for preventing and treating diseases caused by yeast, and for relieving yeast-related symptoms.

[0016] As an alternative to medical treatment, or in addition to it, attempts are nowadays being made to utilize other health care means as well. One of the most recent methods is to use health-promoting nutrients or natural products, which have in fact been warmly welcomed by consumers. Health-promoting products inhibiting yeast growth and activity would therefore be a highly welcome addition to the range of commercially available products. The products should preferably be pleasing and somehow familiar to the consumer, which would make them easy to adopt as a part of the normal daily diet, for example.

[0017] The effects of probiotics as anti-microbial agents have been described in the literature of the art. Lactic acid bacteria are capable of producing anti-microbial compounds, organic acids, lactic acid, fatty acids, hydrogen peroxide, diacetyl, carbon dioxide, and bacteriocins, which enables them to inhibit the growth of pathogenic microbes (McGroarty JA. Probiotic use of lactobacilli in the human female urogenital tract. *FEMS Immunol Med Microbiol* 1993;6:251-264). Some strains of *Lactobacillus acidophilus* prevented the growth of *Candida in vitro* by producing hydrogen peroxide (Jack M, Wood JB, Berry DR. Evidence for the involvement of thiocyanate in the inhibition of *Candida albicans* by *Lactobacillus acidophilus*. *Microbios* 1990;62:37-46; Fitzsimmons N, Berry DR. Inhibition of *Candida albicans* by *Lactobacillus aci-*

acidophilus: evidence for the involvement of a peroxidase system. *Microbios* 1994;80:125-133). It has been discovered that *Lactobacillus rhamnosus* LGG ATCC 53103 also produces an anti-microbial compound, possibly a short-chain fatty acid, that inhibits the *in vitro* growth of *Escherichia coli*, *Pseudomonas*, *Salmonella*, *Streptococcus*, *Bacillus*, *Clostridium*, and *Bifidobacterium*, for example (Silva M, Jacobus NV, Deneke C, Gorbach SL. Antimicrobial substance from a human *Lactobacillus* strain. *Antimicrobial Agents Chemother* 1987;31:1231-1233).

[0018] Lactic acid bacteria may also prevent the adhesion of other microbes to epithelial cells. For example, some *Lactobacillus acidophilus* and *L. casei* strains have been found to prevent 22 - 46% of the adhesion of *C. albicans* to uroepithelial cells in *in vitro* conditions (Reid G, Tieszer C, Lam D. Influence of lactobacilli on the adhesion of *Staphylococcus aureus* and *Candida albicans* to fibers and epithelial cells. *J Indust Microbiol* 1995;15:248-253). In animal tests *Lactobacillus rhamnosus* LGG has been discovered to reduce the amount of *C. albicans* in the gastrointestinal tract of mice and candidosis in the mouth area by stimulating a cell-mediated immune response to antibodies of *C. albicans*. (Wagner RD, Pierson C, Warner T, Dohnalek M, Farmer J, Roberts L et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. *Infect Immun* 1997;65:4165-4172; Wagner RD, Pierson C, Warner T, Dohnalek M, Hilty M, Balish E. Probiotic effects of feeding heat-killed *Lactobacillus acidophilus* and *Lactobacillus casei* to *Candida albicans* - colonized immunodeficient mice. *J Food Protect* 2000;63 :638-644).

[0019] When acting together, *Lactobacillus* LC 705 and *Propionibacterium freudenreichii* ssp. *shermanii* PJS have been discovered to inhibit yeast growth in yoghurts and curd cheese (Suomalainen T, Mäyrä-Mäkinen A. Propionic acid bacteria as protective cultures in fermented milks and breads. *Lait* 1999;79:165-174).

[0020] Lactic acid bacteria and their cellular structures may activate the resistance of the organ system by increasing the activity of macrophages and natural killer cells, the amount of T and B cells and the proportion of antibodies (Perdigon G, Alvarez s, Rachid M, Agüero G, Gobbato N. Symposium: Probiotic bacteria for humans: Clinical systems for evaluation of effectiveness. Immune system stimulation by probiotics. *J Dairy Sci* 1995;78:1597-1606).

[0021] *Lactobacillus rhamnosus* LGG has also been found to enhance the normal resistance of the intestines against harmful bacteria, viruses,

and yeasts (Kaila M, Isolauri E, Soppi E et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human *Lactobacillus* strain. *Pediatr Res* 1992;32:141-144; Wagner et al. 1997). In animal tests *Lactobacillus* GG has also increased the content of secretory IgA in saliva (Negretti F, Casetta P, Clerici-Bagozzi D, Marini A. Researches on the intestinal and systemic immunoresponses after oral treatments with *Lactobacillus* GG in rabbit. *Phisiopath Clin* 1997;7:15-21). The secretory IgA of the mucosal membrane is known to protect the respiratory ducts, gastrointestinal tract, and urogenital organs against infections (Nagura H. Mucosal defence mechanism and secretory IgA system. *Bifidobacteria Microflora* 1990;9: 17-25). Lactic acid bacteria may thus also reduce infections of the respiratory tract and the gastrointestinal tract, indications of which have already been obtained in studies conducted among day-care children (Hatakka K, Savilahti F, Pönkä A, Meurman JH, Poussa T, Näse L, Saxelin M, Korpela R. The effect of long-term consumption of a probiotic milk on the infections of children attending day care centres: a double-blind randomised trial. Submitted to BMJ in May, 2000).

BRIEF DESCRIPTION OF THE INVENTION

[0022] It is an object of the present invention to provide means enabling the growth and activity of yeast in humans and in animals to be inhibited or reduced. This is achieved by the product, use and method of the invention, which are characterized by what is stated in the independent claims. Preferred embodiments of the invention are disclosed in the dependent claims.

[0023] The present invention is based on using specific probiotics for inhibiting yeast growth and activity, for preventing and treating diseases caused by yeast, and for relieving yeast-related symptoms in humans and in animals.

[0024] The invention thus relates to the use of the microbes *Lactobacillus rhamnosus* LGG, ATCC 53103, *Lactobacillus rhamnosus* LC705, DSM 7061, and *Propionibacterium freudenreichii* ssp. *shermanii* PJS, DSM 7067 for inhibiting yeast in humans and in animals.

[0025] For the inventive purpose the bacteria may be consumed separately or in a combination. They can be consumed as such, for example in the form of a lyophilized product, or used as an additive or an ingredient of edible products, such as dairy products and drinks. For the preparation of a combination, mixed cultures or pure cultures of each bacterium can be used.

The combination can also be prepared in a unit dosage form, such as a capsule. The capsule may contain all the above bacteria, preferably in the form of lyophilized cultures, or a series of three capsules may be prepared, one for each bacterium.

5 **[0026]** The invention thus also relates to the use of the bacteria *Lactobacillus rhamnosus* LGG, ATCC 53103, *Lactobacillus casei* ssp. *rhamnosus* LC705, DSM 7061, and *Propionibacterium freudenreichii* ssp. *shermanii* PJS, DSM 7067 for preparing a product for inhibiting yeast.

10 **[0027]** The product can be a food industry product or pharmaceutical industry product, for example, or a health-promoting or a natural product. Preferred products include health-promoting dairy products, such as a cheese, into which the microbes are added in connection with the manufacture of the product. The microbes may also act as starters and as elements forming the structure of the cheese or other product. A second preferred product group includes pharmaceutical preparations, particularly tablets and capsules, that contain auxiliary agents and additives commonly used in these products, and possibly also other active ingredients, in addition to the above micro-organisms. Particularly preferred products include preparations for oral consumption, such as tablets and capsules, containing xylitol, in addition to LGG, LC705, and PJS. Apart from the
15 microbes used according to the invention, the products may contain other microbes as well.
20

[0028] The bacteria, combinations and other products disclosed herein have an effect on the growth and activity of yeast appearing in the human organ system and they prevent yeast infections. They are thus useful for preventing disorders and diseases caused by yeast, for relieving symptoms related thereto, and for general health improvement.
25

[0029] The invention further relates to a method for inhibiting yeast growth and for preventing or treating diseases caused by yeast or for relieving yeast-related symptoms in humans and in animals, the method comprising administering the microbes *Lactobacillus rhamnosus* LGG, ATCC 53103, *Lactobacillus casei* ssp. *rhamnosus* LC705, DSM 7061, and *Propionibacterium freudenreichii* ssp. *shermanii* PJS, DSM 7067 to an individual in need thereof in an amount sufficient to produce the desired result.
30

DETAILED DESCRIPTION OF THE INVENTION

[0030] The present invention thus relates to the use of specific probiotics for inhibiting yeast growth and activity in the organ system of humans or animals.

5 **[0031]** Probiotics are live microbes that, when administered to humans or animals, promote the health of the host by improving the microbial balance in the intestines; in this way, or in addition to this, probiotics may have many other useful properties as well.

10 **[0032]** The most important probiotics are lactic acid bacteria, propionic acid bacteria and bifido bacteria. These belong inherently to the organ system of humans and animals. Lactobacilli are an important part of the normal bacterial flora of human organ system (Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. *Rev Infect Dis* 1990;12:856-872). Propionic bacteria, in turn,
15 appear on the skin and in the gastrointestinal tract (MacFarlane GT, Allison C, Gibson SAW, Cummings JH. Contribution of the microflora to proteolysis in the human large intestine. *J Appl Bacteriol* 1988;64:37-46). Due to their safety and health-promoting effects, probiotics are often used in foodstuffs as well.

20 **[0033]** The strains *Lactobacillus rhamnosus* LGG, ATCC 53103, *Lactobacillus casei* ssp. *rhamnosus* LC705, DSM 7061, and *Propionibacterium freudenreichii* ssp. *shermanii* PJS, DSM 7067 to be used in the invention have been described in the prior art.

25 **[0034]** *Lactobacillus rhamnosus* GG (LGG) has been described for example in US Patent 5,032,399, Gorbach & Goldin. The strain has been isolated from human feces, it is able to grow well in pH 3 and survives even lower pH values as well as high bile acid contents. The strain exhibits excellent adhesion to both mucus and epithelial cells. Lactic acid yield from glucose is good: when grown in MRS broth, the strain produces 1.5 - 2% of lactic acid. The strain does not ferment lactose. The strain employs the following carbohydrates:
30 D-arabinose, ribose, galactose, D-glucose, D-fructose, D-mannose, rhamnose, dulcitol, inositol, mannitol, sorbitol, N-acetylglucosamine, amygdalin, arbutin, esculin, salicin, cellobiose, maltose, saccharose (slowly), trehalose, melezitose, gentiobiose, D-tagatose, L-fucose, and gluconate. The strain grows well at +15 - 45°C, the optimum temperature being 30 - 37°C. *Lactobacillus rhamnosus* GG is
35 deposited with the depository authority American Type Culture Collection under accession number ATCC 53103.

[0035] *Lactobacillus rhamnosus* GG is a natural bacterial strain in humans and its probiotic effects have been widely studied (Saxelin M. *Lactobacillus* GG - a human probiotic strain with thorough clinical documentation. *Food Rev Int* 1997;13:293-313). It remains viable in the gastrointestinal tract and is capable of temporarily colonizing the intestines (Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S. Survival of *Lactobacillus* species (strain GG) in human gastrointestinal tract. *Dig Dis Sci* 1992;37:121-128). LGG seems to be capable of colonizing, at least temporarily, the oral cavity as well, because the bacterium was found in the test persons' saliva for as long as two weeks after a seven-day period of LGG yoghurt consumption had ended (Meurman JH, Antila H, Salminen S. Recovery of *Lactobacillus* strain GG (ATCC 53103) from saliva of healthy volunteers after consumption of yoghurt prepared with the bacterium. *Microbiol Ecol Health Dis* 1994;7:295-298). LGG is currently added to a number of commercially available sour milk and juice products (Gefilus®).

[0036] *Lactobacillus casei* ssp. *rhamnosus* LC705 is described in greater detail in FI Patent 92498, Valio Oy. LC705 is a gram-positive short rod occurring in chains; it is homofermentative; weakly proteolytic; grows well at +15-45°C; does not produce ammonia from arginine; is catalase-negative; when grown in MRS broth (LAB M), the strain produces lactic acid (1.6%) having the optical activity of the L(+) configuration; the strain decomposes citrate (0.169%), thereby producing diacetyl and acetoin; the strain ferments at least the following carbohydrates (sugars, sugar alcohols): ribose, galactose, D-glucose, D-fructose, D-mannose, L-sorbose, rhamnose, mannitol, sorbitol, methyl-D-glucoside, N-acetylglucosamine, amygdalin, arbutin, esculin, salicin, cellobiose, maltose, lactose, sucrose, trehalose, melezitose, gentiobiose, D-turanose and D-tagatose. LC705 adheres weakly to mucus cells, but moderately to epithelial cells. The viability of the strain is good in low pH values and high bile acid contents. The strain survives well a salinity of 5% and fairly well a salinity of 10%. *Lactobacillus casei* ssp. *rhamnosus* LC705 is deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM) under accession number DSM 7061.

[0037] *Lactobacillus rhamnosus* LC705 is used for example in the manufacture of Emmental cheese to prevent butyric acid fermentation caused by clostridia. The strain is also used in foodstuffs where it functions as an inhibitor of

yeast and mold growth. In biological preservation LC705 strain is combined with *Propionibacterium freudenreichii* ssp. *shermanii* PJS (FI 92498).

5 **[0038]** *Propionibacterium freudenreichii* ssp. *shermanii* JS (PJS) is also described in greater detail in FI Patent 92498, Valio Oy. PJS is a gram-positive short rod; it ferments glucose, fructose, galactose and lactose; it ferments well lactate; and its optimum growth temperature is 32°C. The viability of the strain in low pH values and high bile acid contents is excellent. *Propionibacterium freudenreichii* ssp. *shermanii* JS is deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM) under accession number DSM 7067.

10 **[0039]** In addition to the microbes to be used in accordance with the invention, the products to be manufactured may also contain other micro-organisms, such as micro-organisms and probiotics contained in starters used in the dairy industry. There are numeral well-documented strains of starters
15 that are commercially available from producers such as Hansen A/S, Denmark, and Danisco/Wiesby GmbH, Germany.

20 **[0040]** The micro-organisms to be used according to the invention are cultivated using conventional methods, either as pure cultures or as different mixed cultures. The cultures can be used as such, or they can be processed as desired, for example purified, concentrated, lyophilized or finished to produce different products. The preparation of the micro-organisms to be used according to the invention is described in detail for example in publications FI 92498 and FI 20010157.

25 **[0041]** According to the invention, a sufficient amount of probiotics is used to produce the desired yeast inhibiting effect. The amount of each individual probiotic may therefore vary within a large range depending on for example the total amount of probiotics cells, the total daily dose and on other properties and ingredients of the product. The probiotics content in a daily dose of a combination is usually about 10^6 - 10^{10} cfu.

30 **[0042]** According to the invention, the probiotics are suitable for consumption as such or formulated as capsules, pills, or tablets, for example, in processes conventionally applied for preparing pharmaceutical products. The probiotics to be used according to the invention can also be added to different edible products, such as foodstuffs, products of the beverage and confectionary industries, to health-promoting products, natural products, etc.
35 Within the scope of the present invention, dairy products containing the spe-

cific probiotics, particularly cheeses and spreads, yoghurts and other sour milk products, and children's foods, juices and soups, as well as capsules, pills, and tablets are considered as preferred embodiments.

5 [0043] The end products are produced using conventional methods, the probiotics being added either during the process of preparing the product or afterwards, during the finishing.

10 [0044] The tests, which are described in greater detail in the publication, were carried out to study the effects of the probiotics to be used according to the invention on inhibiting oral yeast growth. The most common one of these yeasts, *Candida albicans*, which is a good representative of yeast species and widely present in the human organism, is most useful also as a model organism for other yeast species appearing in the mouth and in other parts of the organ system. The results presented in the examples show that the probiotics used according to the invention have a statistically significant reducing effect on the amount of oral yeasts. According to preliminary results it is evident that the invention is applicable in inhibiting, reducing and slowing down to a wide extent the growth and activity of yeast appearing also in other parts of the organ system, such as the intestinal tract and the urogenital area.

15 [0045] The invention will be described in detail with reference to the following examples, which are provided only to illustrate the invention and are not to be considered to restrict its scope of protection in any way.

Example 1

25 [0046] The effect of probiotics on the occurrence of *Candida albicans*

30 [0047] The main purpose of the study was to find out whether a probiotic combination containing lacto bacilli and propionic acid bacteria could be used for reducing the occurrence of *Candida albicans* in the mouth. Emmental-type cheese containing live *Lactobacillus rhamnosus* LGG, ATCC 53103, *Lactobacillus rhamnosus* LC705, DSM 7061, and *Propionibacterium freudenreichii* ssp. *shermanii* PJS, DSM 7067 microbes was selected as the test material. Cheese was chosen because it is a product that belongs to an ordinary diet, it is pleasant to eat and easy to portion out in accordance with the study purpose. The cheese used as a reference was Edam cheese that did not contain the three bacterial strains in question but normal starter microbes, which were lactococci.

35

[0048] 240 people were recruited for the study, their ages varying from 70 to 100 years.

[0049] The study was carried out as a placebo-controlled double blind test, with parallel study groups. The total study period was 19 weeks, with a run-in period of 3 weeks and 16 weeks of intervention. Use of foodstuffs containing probiotic bacteria was forbidden during the entire study. The list of forbidden foodstuffs contained e.g. Emmental and Polar cheeses, curd cheese, sour milk products containing live lactic acid bacteria, probiotics juices and different capsules and similar compressed products.

[0050] During the entire study period, the test persons adhered to their usual habits regarding oral hygiene and their normal ways of living.

[0051] Intervention: The cheese intervention continued for 16 weeks (wk). During this time half of the test persons consumed 50 g (= 6 - 7 slices) of cheese containing probiotic bacteria daily, the other half consuming the same amount of control cheese. The cheeses were eaten unheated after the morning and evening meals, medication and teeth wash. The probiotics cheese contained 10^7 cfu/g of *L. rhamnosus* LGG, 10^7 cfu/g of *L. rhamnosus* LC705, and 10^7 cfu/g of *P. freudenreichii* ssp. *shermanii* PJS. Thus the total amount of bacteria was 10^9 - 10^{10} cfu/day.

[0052] Clinical mouth controls: Mouth controls were carried out and saliva samples taken at the old people's homes / nursing homes where the test persons lived in. The clinical checks included recording filled and removed teeth and those affected by caries (DMF). Also the condition of the periodontium was checked and classified according to the CPI index. Changes, if any, in the mucosal membrane of the mouth were recorded (including infections, discolorations, wounds, lichenoid lesions and ulcers, hyperplasia, leucoplakia, erythroplakia, and other). The clinical controls were carried out at the beginning of the study (0 wk) and at the end of it (16 wk).

[0053] Saliva samples: Saliva samples to determine yeasts, the rate of saliva secretion and buffer capacity were taken between 8 a.m. and 11 a.m. every morning. An attempt was made to take the sample always at the same time from each person. The test persons were not allowed to eat or wash their teeth for one hour before the taking of the sample. Saliva samples for yeast analysis were taken at the beginning of the study (0 wk), in the middle of it (8 wk) and at the end of it (16 wk). The rate of saliva secretion and the buffer ca-

capacity were determined from the first sample (0 wk) and the last samples (16 wk).

5 **[0054]** Yeasts were determined from saliva by taking samples from the mucosal membrane of the mouth with a cotton stick. The yeasts (*mainly Candida albicans*) were detected using the Dentocult CA cultivation method, in which the tubes are incubated in an incubator at 37°C for 2 days, yeast growth being then determined semi-quantitatively on a scale of 0 - 3 (0 = no colonies, 1 = 1 - 20 cfu/slip, 2 = 21 - 50 cfu/slip, 3 > 50 cfu).

10 **[0055]** Saliva secretion rate was determined by measuring both resting saliva and stimulated saliva. The limit value for hyposalivation is considered to be 0.1 ml/min of resting saliva; therefore resting saliva was collected for 15 min (1.5 ml/15 min). Stimulated saliva was collected for 5 minutes (the hyposalivation limit being 3.5 ml/ 5 min).

15 **[0056]** Saliva buffer capacity is associated with the rate of secretion. For this reason buffer capacity was measured using the Dentobuff test. The test was carried out on stimulated saliva, because the buffer capacity of resting saliva is always poor.

20 **[0057]** At the end of the intervention period the amount of yeast formed the primary response variable in the study. The differences in the occurrence and the amounts of yeast between the groups were tested using the Chi Square test. In addition, the occurrence of yeast or the amount thereof in the baseline situation and demographic factors (such as age, gender, prostheses), if any, were taken into account using a logistic regression analysis. In this connection, the saliva secretion rate and buffer capacity were also taken into
25 account as explanatory factors. High saliva contents were analysed correspondingly. Changes in saliva secretion rate and the buffer capacity were described.

30 **[0058]** The results are shown in the following tables, in which A represents the group that ate the probiotics cheese, B being the control group. The number of colonies has been presented as follows:

[0059] 0 = no colonies

[0060] 1 = 1 - 20 cfu/slip

[0061] 2 = 20 - 50 cfu/slip

[0062] 3 = more than 50 cfu/slip

35 **[0063]** Table 1 shows the precise yeast measurement results at the beginning of the study and after 8 and 16 weeks of intervention for persons

from whom all the three measurements were obtained (in group A n = 92, in group B n = 100). Table 2 shows classified yeast amounts at the beginning of the study and after 8 and 16 weeks of intervention for persons from whom all the three measurements were obtained (in group A n = 92, in group B n = 100).

Table 1

Precise yeast results at the beginning of the study and after 8 and 16 weeks of intervention

		A		B	
		n	%	n	%
Baseline	0	27	29.3	30	30.0
	1	37	40.2	42	42.0
	2	17	18.5	14	14.0
	3	11	12.0	14	14.0
8 wk	0	32	34.8	37	37.0
	1	37	40.2	32	32.0
	2	10	10.9	15	15.0
	3	13	14.1	16	16.0
16 wk	0	35	38.0	33	33.0
	1	38	41.3	33	33.0
	2	11	12.0	17	17.0
	3	8	8.7	17	17.0

Table 2

Classified yeast contents at the beginning of the study and after 8 and 16 weeks of intervention

5 0 vs. 1-4

		A		B	
		n	%	n	%
Baseline	0	27	29.3	30	30.0
	1-4	65	70.7	70	70.0
8 wk	0	32	34.8	37	37.0
	1-4	60	65.2	63	63.0
16 wk	0	35	38.0	33	33.0
	1-4	57	62.0	67	67.0

0-1 vs. 2-4

		A		B	
		n	%	n	%
Baseline	0-1	64	69.6	72	72.0
	2-4	28	30.4	28	28.0
8 wk	0-1	69	75.0	69	69.0
	2-4	23	25.0	31	31.0
16 wk	0-1	73	79.3	66	66.0
	2-4	19	20.7	34	34.0

10 0-2 vs. 3-4

		A		B	
		n	%	n	%
Baseline	0-2	81	88.0	86	86.0
	3-4	11	12.0	14	14.0
8 wk	0-2	79	85.9	84	84.0
	3-4	13	14.1	16	16.0
16 wk	0-2	84	91.3	83	83.0
	3-4	8	8.7	17	17.0

[0064] Groups A and B were compared to each other for yeast occurrence after 8 and 16 weeks of intervention both directly and taking into account interfering factors, if any. These factors consist of age, gender, type of living, number of diagnoses, amount of medication, BMI, saliva flow rate, buffer capacity, and prosthesis, if any. The interfering factors were taken into account by using stepwise logistic regression. The group and the baseline yeast situ-

ation are forced into a model (block 1) and the interfering factors interfering on the list are taken into account stepwise (block 2; significance criterion p being less than 0.15). The results are shown in the following tables, in which table 3 shows a direct comparison in the group of relatively high yeast occurrence, i.e. classes 2 - 4, table 4 takes into account the interfering factors, table 5 shows a direct comparison in the group of high yeast occurrence, i.e. classes 3 - 4, and table 6 takes into account the interfering factors. In these tables abbreviation OR = odds ratio and abbreviation CI for OR = confidence interval for odds ratio.

Table 3**Relatively high yeast occurrence (classes 2 - 4)**

a) after 8 weeks

	B	p-value	OR	95% CI for OR
Group A	-0.469	0.178	0.625	0.316 to 1.239
Initial yeast 2-4	2.382	<0.0001	10.825	5.450 to 21.500
Constant	-1.520	<0.0001		

b) after 16 weeks

	B	p-value	OR	95% CI for OR
Group A	-0.946	0.014	0.388	0.182 to 0.826
Initial yeast 2-4	2.244	<0.0001	9.4355	4.461 to 19.957
Constant	-1.390	<0.0001		

Table 4
Relatively high yeast occurrence (classes 2 - 4), with interfering factors taken into account

		B	p-value	OR	95% CI for OR
Step 1	Group A	-1.229	0.0082	0.293	0.118 to 0.728
	Initial yeast 2-4	1.911	<0.0001	6.757	2.875 to 15.884
	Buffer capacity		0.0002		
	Buffer capacity (H)	-2.318	<0.0001	0.098	0.032 to 0.299
	Buffer capacity (M)	-1.614	0.0113	0.199	0.057 to 0.694
	Constant	0.481	0.3896	1.617	
Step 2	Group A	-1.378	0.0043	0.252	0.098 to 0.649
	Initial yeast 2-4	1.845	<0.0001	6.325	2.636 to 15.178
	Buffer capacity		0.0003		
	Buffer capacity (H)	-2.388	<0.0001	0.092	0.029 to 0.290
	Buffer capacity (M)	-1.588	0.0152	0.204	0.057 to 0.737
	Prosthesis (status 1)	1.117	0.0390	3.057	1.058 to 8.831
	Constant	-0.246	0.7165	0.782	

5

Table 5
High yeast occurrence (classes 3 - 4)

a) after 8 weeks

10

	B	p-value	OR	95% CI for OR
Group A	0.029	0.956	1.029	0.373 to 2.837
Initial yeast 3-4	4.022	<0.0001	55.8	18.7 to 166.8
Constant	-2.782	<0.0001		

b) after 16 weeks

	B	p-value	OR	95% CI for OR
Group A	-0.824	0.098	0.439	0.165 to 1.164
Initial yeast 3-4	2.420	<0.0001	11.244	4.186 to 30.208
Constant	-2.142	<0.0001		

15

Table 6

High yeast occurrence (classes 3 - 4), with interfering factors taken into account

5

		B	p-value	OR	95% CI for OR
Step 1	Group A	-1.067	0.0657	0.344	0.110 to 1.072
	Initial yeast 3-4	2.221	0.0003	9.216	2.798 to 30.359
	Buffer capacity		0.0370		
	Buffer capacity (H)	-1.629	0.0142	0.196	0.053 to 0.721
	Buffer capacity (M)	-0.551	0.4525	0.576	0.137 to 2.428
	Constant	0.982	0.1136	0.375	
Step 2	Group A	-1.213	0.0437	0.297	0.091 to 0.966
	Initial yeast 3-4	2.300	0.0002	9.974	2.979 to 33.396
	Buffer capacity		0.0238		
	Buffer capacity (H)	-1.807	0.0080	0.164	0.043 to 0.624
	Buffer capacity (M)	-0.726	0.3339	0.484	0.111 to 2.109
	Generation of women	-0.956	0.0991	0.385	0.124 to 1.197
	Constant	-0.154	0.8452	0.857	
Step 3	Group A	-1.475	0.0222	0.229	0.065 to 0.810
	Initial yeast 3-4	2.213	0.0004	9.145	2.704 to 30.924
	Buffer capacity		0.0256		
	Buffer capacity (H)	-1.846	0.0086	0.158	0.040 to 0.625
	Buffer capacity (M)	-0.781	0.3151	0.458	0.100 to 2.101
	Generation of women	-1.371	0.0305	0.254	0.073 to 0.879
	Prosthesis (status 1)	1.274	0.1003	3.576	0.782 to 16.350
	Constant	-0.713	0.4344	0.490	

[0065] The results show that ageing, use of prostheses and reduced salivation are clearly associated with increased amount of yeast. Lower initial yeast amounts, in turn, were discovered with test persons who reported that they had regularly used products containing lactic acid bacteria before the study.

[0066] When examining the yeast results alone, without taking into account interfering factors, it can be seen that yeast amounts decreased more in the probiotics group than in the control group. Irrespective of whether the focus is on studying yeast occurrence (1-4), relatively high yeast occurrence (2-4), or high yeast occurrence (3-4), the results show that the proportion of those belonging to the probiotics group decreases in all of these groups as the intervention proceeds. The proportion of those belonging to the control group, in turn, does not change equally clearly. On the contrary, the proportion of

those belonging to the groups of higher yeast occurrence seems even to increase in the control group.

5 **[0067]** When interfering factors are taken into account, it is observed that probiotics intervention produces a statistically significant reduction in the occurrence of both relatively high (2-4) and high (3-4) yeast amounts, as compared with the control group.

10 **[0068]** The results thus show that by using cheese containing the above probiotics, it was possible to reduce yeast amounts significantly. The present invention is thus useful for inhibiting yeast in accordance with the objectives of the invention.

CLAIMS

1. Use of the microbes *Lactobacillus rhamnosus* LGG, ATCC 53103, *Lactobacillus rhamnosus* LC705, DSM 7061, and *Propionibacterium freudenreichii* ssp. *shermanii* PJS, DSM 7067 for preparing a product for inhibiting yeast.
- 5 2. Use of microbes according to claim 1, **characterized** by preparing a product of the food industry or the pharmaceutical industry, a health promoting product, or natural products.
3. Use of microbes according to claim 1, **characterized** by preparing a food product.
- 10 4. Use of microbes according to claim 3, **characterized** by preparing a dairy product, preferably cheese.
5. Use of microbes according to any one of claims 1 to 4, **characterized** in that also other, conventional (starter) bacteria are used in the preparation.
- 15 6. Use of microbes according to any one of claims 1 to 5, **characterized** by preparing a unit dosage form containing the microbes.
7. Use of microbes according to claim 6, **characterized** in that the dosage form is a preparation for oral consumption.
8. Use of microbes according to claim 7, **characterized** in that
- 20 the dosage form is a capsule or a tablet containing xylitol, in addition to the microbes.
9. A method for inhibiting the growth of yeasts and for relieving yeast-related symptoms in animals or humans, the method comprising: administering the microbes *Lactobacillus rhamnosus* LGG, ATCC 53103, *Lactobacillus casei* ssp. *rhamnosus* LC705, DSM 7061, and *Propionibacterium freudenreichii* ssp. *shermanii* PJS, DSM 7061 to an individual in the need thereof in an amount sufficient to produce the desired effect.
- 25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 2003/000813

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 39/05, A61K 39/07, A61K 35/74, A01N 63/00, A23L 1/03, C12N 1/20
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A01N, A61K, A23L, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI-DATA, EPO-INTERNAL, PAJ, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02060276 A1 (VALIO LTD), 8 August 2002 (08.08.2002) --	1-9
A	US 5378458 A (ANNIKA MÄYRÄ-MÄKINEN ET AL), 3 January 1995 (03.01.1995) --	1-9
A	Infection and Immunity, Volume 65, no. 10, October 1997, R. Doug Wagner et al: "Biotherapeutic Effects of Probiotic Bacteria on Candidiasis in Immunodeficient Mice", page 4165 - page 4172 -- -----	1-9

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 January 2004

Date of mailing of the international search report

03 -02- 2004

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Micael Oswald/Eö

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

24/12/2003

International application No.

PCT/FI 2003/000813

WO	02060276	A1	08/08/2002	CA	2434337	A	08/08/2002
				EE	200300351	A	15/12/2003
				EP	1359816	A	12/11/2003
				FI	5009	U	26/07/2001
				FI	109602	B	00/00/0000
				FI	20010157	A,V	26/07/2002
				NO	20033283	A	24/09/2003
<hr/>							
US	5378458	A	03/01/1995	AT	173502	T	15/12/1998
				DE	69322131	D,T	20/05/1999
				DK	576780	T	02/08/1999
				EP	0576780	A,B	05/01/1994
				SE	0576780	T3	
				ES	2125278	T	01/03/1999
				FI	92498	B,C	15/08/1994
				FI	922699	A	11/12/1993
<hr/>							

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI 2003/000813

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **9**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

Claim 9 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.